Valuation: AbbVie Inc.

Market Cap 514B 461B 424B 384B 718B 48,786B 731B 5,043B 2,026B 25,657B 1,928B 1,887B 80,943B P/E 2026 *
38.6x
P/E 2027 * 28.2x
Enterprise Value 576B 516B 475B 430B 804B 54,658B 819B 5,650B 2,270B 28,746B 2,160B 2,114B 90,685B EV / Sales 2026 *
8.51x
EV / Sales 2027 * 7.73x
Free-Float
95.71%
Yield 2026 *
2.33%
Yield 2027 * 2.46%
1 day+1.41%
1 week+3.40%
Current month+12.73%
1 month+12.00%
3 months+12.00%
6 months+44.63%
Current year+29.06%
1 week 281.22
Extreme 281.225
298.74
1 month 257.87
Extreme 257.87
298.74
Current year 190.75
Extreme 190.75
298.74
1 year 190.75
Extreme 190.75
298.74
3 years 135.85
Extreme 135.85
298.74
5 years 113.57
Extreme 113.57
298.74
10 years 55.68
Extreme 55.68
298.74
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Free

Director

59 0.0000%
9/30/26 Free

Director

129 0.0000%
8/14/26 Exercice

Executive/Senior Manager

98,130 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
+1.41%+3.40%+30.98%+112.26% 514B
+3.19%+8.48%+74.25%+153.03% 1,224B
-0.73%+2.09%+46.41%+87.64% 662B
+0.42%+2.88%+54.92%+69.67% 388B
+2.18%+1.55%+72.70%+45.42% 361B
+1.12%+3.80%+35.82%+59.72% 302B
+6.96%+7.55%+11.15%+37.89% 271B
+1.15%+4.19%+59.72%+78.16% 249B
+3.06%+8.58%+44.03%+122.76% 205B
+2.21%+0.51%-20.53%-59.69% 172B
Average +1.89%+2.17%+40.94%+70.69% 434.88B
Weighted average by Cap. +1.29%+2.85%+50.43%+94.09%

Financials

2026 *2027 *
Net sales 67.62B 60.61B 55.78B 50.5B 94.48B 6,420B 96.19B 664B 267B 3,376B 254B 248B 10,652B 73.52B 65.9B 60.65B 54.9B 103B 6,980B 105B 721B 290B 3,671B 276B 270B 11,581B
Net income 14.04B 12.59B 11.58B 10.49B 19.62B 1,333B 19.97B 138B 55.37B 701B 52.69B 51.57B 2,212B 18.97B 17B 15.65B 14.16B 26.5B 1,801B 26.98B 186B 74.8B 947B 71.18B 69.66B 2,988B
Net Debt 61.85B 55.44B 51.02B 46.19B 86.41B 5,872B 87.98B 607B 244B 3,088B 232B 227B 9,742B 54.27B 48.64B 44.77B 40.53B 75.82B 5,152B 77.19B 533B 214B 2,710B 204B 199B 8,548B
Projected Income Statement - Annual - AbbVie Inc.
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-10-30 $294.89 +1.41% 6,867,990
26-10-29 $290.79 +1.68% 4,329,286
26-10-28 $285.99 -0.14% 3,111,349
26-10-27 $286.39 -0.12% 3,269,363
26-10-26 $286.74 +0.39% 4,516,377
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - AbbVie Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
294.89USD
Average target price
283.19USD
Spread / Average Target
-3.97%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AbbVie Inc.
  1. Stock Market
  2. Stocks
  3. ABBV Stock